Construction of the 21,400 m2 plant was first announced in August 2014, and last week an inauguration ceremony took place at Takeda’s Oranienburg, Brandenburg site.
When operations begin at the ‘M3P3’ facility – expected by the end of the year – the plant will produce solid pill and capsule forms of the Japanese pharma firm’s product portfolio, including its gastroenterology drug Protonix (pantoprazole) and its depression treatment Trintellix (vortioxetine).
Several of the products to be made at the facility will be transferred from Takeda’s Osaka, Japan plant as part of the firm’s strategy to optimise its global manufacturing network. The Osaka plant is being transformed into a specialty manufacturing site for Leuplin, Takeda’s treatment for hormone-dependent diseases such as prostate cancer and premenopausal breast cancer.
“We continuously invest in our facilities to advance our technologies in order to ensure a stable supply of high-quality drug products to patients around the world,” Thomas Wozniewski, Global Manufacturing & Supply officer from Takeda said in a statement.
Total cost of construction was around €100m, with the state of Brandenburg and the German federal government contributing €23m in subsidies.